Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 24
Filter
1.
J Diabetes Investig ; 15(7): 906-913, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38445817

ABSTRACT

AIMS/INTRODUCTION: In 2021, the guidelines on gestational weight gain (GWG) were revised and increased by 2-3 kg in Japan. This study aimed to investigate whether the revised guidelines would increase the incidence of babies with excessive birth weight in mothers with diabetes. MATERIALS AND METHODS: This retrospective study included 369 deliveries of women with diabetes whose pre-pregnancy body mass index was below 30 kg/m2 between 1982 and 2021. The primary outcome measure was large for gestational age (LGA). We compared the incidence of LGA between women who gained weight within the previous guidelines and women who gained weight within the revised guidelines. We also compared the incidence of macrosomia, preeclampsia, small for gestational age (SGA), and low birth weight. RESULTS: The incidence of LGA was not significantly different between women who gained weight within the revised guidelines and those within the previous guidelines (34.6% [95% confidence interval 25.6-44.6%] for the revised guidelines vs 28.9% [21.6-37.1%] for the previous guidelines; P = 0.246). Neither was the incidence of macrosomia or preeclampsia significantly different (8.7% [4.0-15.8%] vs 5.6% [2.5-10.8%] and 5.8% [2.1-12.1%] vs 6.3% [2.9-11.7%]; P = 0.264 and 0.824, respectively), while women who gained weight within the revised guidelines had a lower incidence of SGA (1.9% [0.2-6.8%] vs 10.6% [6.0-16.8%]; P = 0.001) and low birth weight (1.0% [0.02-5.2%] vs 7.0% [3.4-12.6%]; P = 0.023). CONCLUSIONS: The revised GWG guidelines could be beneficial in women with diabetes in terms of delivering babies with appropriate birth weight.


Subject(s)
Birth Weight , Gestational Weight Gain , Humans , Female , Pregnancy , Retrospective Studies , Japan/epidemiology , Adult , Infant, Newborn , Fetal Macrosomia/epidemiology , Fetal Macrosomia/etiology , Incidence , Diabetes, Gestational/epidemiology , Infant, Small for Gestational Age , Pregnancy in Diabetics/epidemiology , Body Mass Index , East Asian People
2.
J Diabetes Investig ; 13(10): 1761-1770, 2022 Oct.
Article in English | MEDLINE | ID: mdl-35593737

ABSTRACT

AIMS/INTRODUCTION: This study investigated the time trends of the maternal characteristics and perinatal outcomes of Japanese pregnant women with diabetes. MATERIALS AND METHODS: This retrospective study included 621 deliveries in 429 Japanese women with diabetes between 1982 and 2020. The association of the delivery date with clinical features was analyzed using the generalized estimating equations to adjust for the within-person correlation. RESULTS: The mean age of delivery and the mean diabetes duration increased over time (both P < 0.001), while the prevalence of diabetic retinopathy decreased (P = 0.006). The mean HbA1c values during pregnancy decreased significantly over time (all P < 0.001). The decreasing trends were associated with preterm delivery (P = 0.021) but not with other perinatal outcomes. The time trends were significantly different between patients with type 1 diabetes mellitus and with type 2 diabetes mellitus in large for gestational age (LGA) and stillbirth (both P for interaction <0.05). The rate of LGA decreased among patients with type 2 diabetes (P = 0.003) but not those with type 1 diabetes (P = 0.413). In contrast, the prevalence of stillbirth was decreased among those with type 1 diabetes (P < 0.001) but not those with type 2 diabetes (P = 0.768). The proportion of major congenital anomalies did not change in the overall population (P = 0.259) and among patients with type 2 diabetes (P = 0.229), but it increased among those with type 1 diabetes (P = 0.044), although the difference between those with type 1 diabetes and type 2 diabetes was not statistically significant (P for interaction = 0.166). CONCLUSIONS: Maternal glycemic control has improved over the decades, whereas the improvement of perinatal outcomes has been limited. Perinatal outcomes still need to be improved in Japanese women with diabetes.


Subject(s)
Diabetes Mellitus, Type 1 , Diabetes Mellitus, Type 2 , Diabetes, Gestational , Diabetes Mellitus, Type 1/complications , Diabetes Mellitus, Type 1/epidemiology , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/epidemiology , Female , Glycated Hemoglobin , Humans , Infant, Newborn , Japan/epidemiology , Pregnancy , Pregnancy Outcome/epidemiology , Pregnant Women , Retrospective Studies , Stillbirth , Weight Gain
3.
J Obstet Gynaecol Res ; 47(12): 4164-4170, 2021 Dec.
Article in English | MEDLINE | ID: mdl-34488239

ABSTRACT

AIM: To investigate the incidence of major congenital malformations in Japanese women with pregestational diabetes, and to determine the cutoff value of hemoglobin A1c (HbA1c) in the first trimester associated with congenital malformations. METHODS: This retrospective cohort study included singleton pregnancies in Japanese women with pregestational diabetes, including type 1 and type 2 diabetes, and specific types of diabetes due to other causes. The primary outcome was the incidence of major congenital malformations. The secondary outcome was the incidence of all congenital malformations. The cutoff value of HbA1c for congenital malformations was calculated using receiver operating characteristic curve analysis. The adjusted odds ratios (aOR) of major congenital malformations were calculated using multiple logistic regression analyses. RESULTS: This study enrolled 292 patients, including 132 (45.2%) with type 1 diabetes, 156 (53.4%) with type 2 diabetes, and 4 (1.4%) with other specific types. The incidence rates of major congenital malformations and all congenital malformations were 7.2% (21/292) and 12.7% (37/292), respectively. The cutoff value of HbA1c in the first trimester for major malformations and for all congenital malformations was 6.5%. HbA1c ≥ 6.5% was significantly associated with major malformations (aOR 3.5; 95% confidence interval: 1.2-12.6; p = 0.018). CONCLUSION: The incidence of major congenital malformations significantly increased in pregnant Japanese women with HbA1c values of 6.5% or higher. The recommended HbA1c value during the first trimester used in other countries can be applied to pregnant Japanese women.


Subject(s)
Congenital Abnormalities , Diabetes Mellitus, Type 1 , Diabetes Mellitus, Type 2 , Female , Glycated Hemoglobin/analysis , Humans , Japan/epidemiology , Pregnancy , Pregnancy Trimester, First , Retrospective Studies
4.
BMC Pregnancy Childbirth ; 21(1): 582, 2021 Aug 23.
Article in English | MEDLINE | ID: mdl-34425784

ABSTRACT

BACKGROUND: Obese pregnant women are known to experience poorer pregnancy outcomes and are at higher risk of postnatal arteriosclerosis. Hence, weight control during and after pregnancy is important for reducing these risks. The objective of our planned randomized controlled trial is to evaluate whether the rate of change in body weight in obese women before pregnancy to 12 months postpartum would be lower with the use of an intervention consisting of Internet of Things (IoT) devices and mobile applications during pregnancy to 1 year postpartum compared to a non-intervention group. METHODS: Women will be recruited during outpatient maternity checkups at four perinatal care institutions in Japan. We will recruit women at less than 30 weeks of gestation with a pre-pregnancy body mass index ≥ 25 kg/m2. The women will be randomly assigned to an intervention or non-intervention group. The intervention will involve using data (weight, body composition, activity, sleep) measured with IoT devices (weight and body composition monitor, activity, and sleep tracker), meal records, and photographs acquired using a mobile application to automatically generate advice, alongside the use of a mobile application to provide articles and videos related to obesity and pregnancy. The primary outcome will be the ratio of change in body weight (%) from pre-pregnancy to 12 months postpartum compared to before pregnancy. DISCUSSION: This study will examine whether behavioral changes occurring during pregnancy, a period that provides a good opportunity to reexamine one's habits, lead to lifestyle improvements during the busy postpartum period. We aim to determine whether a lifestyle intervention that is initiated during pregnancy can suppress weight gain during pregnancy and encourage weight loss after delivery. TRIAL REGISTRATION: UMIN: UMIN (University hospital Medical Information Network) 000,041,460. Resisted on 18th August 2020. https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000047278.


Subject(s)
Gestational Weight Gain , Mobile Applications , Obesity, Maternal/prevention & control , Postpartum Period/physiology , Weight Loss , Female , Health Behavior , Humans , Internet of Things/instrumentation , Japan/epidemiology , Life Style , Pregnancy , Randomized Controlled Trials as Topic , Research Design
5.
Endocr J ; 67(4): 427-437, 2020 Apr 28.
Article in English | MEDLINE | ID: mdl-31969529

ABSTRACT

For women with gestational diabetes mellitus (GDM), the evaluation of glucose tolerance (GT) in the early postpartum period is universally recommended. Nevertheless, few studies have evaluated the risk factors for T2DM on the basis of GT data obtained during the early postpartum period. We aimed to identify the risk factors for type 2 diabetes mellitus (T2DM) by evaluating GT in the first 12 weeks postpartum (12wPP) in women with GDM and to categorize the risk using a combination of the principal risk factors. This retrospective multicenter observational study included 399 East Asian women with GDM who underwent a 75-g oral glucose tolerance test (OGTT) within 12wPP, which was repeated annually or biennially and used to identify the postpartum development of T2DM. Forty-three women (10.8%) developed T2DM during a median follow-up period of 789 ± 477 days. The independent risk factors for T2DM were pre-pregnancy obesity (BMI ≥25 kg/m2), early postpartum impairment in glucose tolerance (IGT), and an early postpartum glycated hemoglobin (HbA1c) ≥5.7%. The odds ratios (95% confidence intervals) for T2DM were 3.2 (1.3-7.8) in women with either early postpartum IGT or pre-pregnancy obesity, 9.2 (3.0-28.3) in those with early postpartum IGT, pre-pregnancy obesity, and HbA1c <5.7%, and 51.4 (16.1-163.9) in those with early postpartum IGT, pre-pregnancy obesity, and HbA1c ≥5.7%, compared with those without obesity or IGT. T2DM risk in East Asian women with GDM should be stratified according to pre-pregnancy obesity and early postpartum IGT, and these patients should be followed up and receive appropriate care for their risk category.


Subject(s)
Diabetes Mellitus, Type 2/diagnosis , Diabetes Mellitus, Type 2/epidemiology , Diabetes, Gestational/physiopathology , Postpartum Period , Adult , Blood Glucose/analysis , Body Mass Index , Female , Glucose Intolerance/physiopathology , Glucose Tolerance Test , Glycated Hemoglobin/analysis , Humans , Japan , Obesity/complications , Odds Ratio , Pregnancy , Retrospective Studies , Risk Factors
6.
J Diabetes Investig ; 11(1): 216-222, 2020 Jan.
Article in English | MEDLINE | ID: mdl-31199576

ABSTRACT

AIMS/INTRODUCTION: To compare pregnancy outcomes between women with gestational diabetes mellitus (GDM) diagnosed early and late in pregnancy in Japan. MATERIALS AND METHODS: We examined women diagnosed with GDM in this multi-institutional retrospective study. Women were divided into two groups by gestational age at diagnosis: <24 weeks of gestation (early group, 14.4 ± 4.2 weeks) and ≥24 weeks of gestation (late group, 29.6 ± 3.4 weeks). Dietary counseling with self-monitoring of blood glucose with or without insulin therapy was initiated for both groups. Pregnancy outcomes were compared between the groups. RESULTS: Data from 600 early and 881 late group participants from 40 institutions were included. Although pre-pregnancy body mass index was higher in the early group than in the late group, gestational weight gain was lower in the early group. Hypertensive disorders of pregnancy and cesarean section were more prevalent in the early than in the late group (9.3% vs 4.8%, P < 0.001; 34.2% vs 32.0%, P < 0.001, respectively). The prevalence of large-for-gestational-age infants was higher in the late than in the early group (24.6% vs 19.7%, respectively, P = 0.025). There was no significant difference in other neonatal adverse outcomes between the groups. Multiple logistic regression analysis showed that early group, nulliparity and pre-pregnancy body mass index were associated with hypertensive disorders of pregnancy. CONCLUSIONS: These results suggest that maternal complications, including hypertensive disorders of pregnancy and cesarean delivery, were higher in the early group than in the late group. Earlier intervention for GDM might be associated with a reduction in large-for-gestational-age infants.


Subject(s)
Diabetes Mellitus, Type 2/physiopathology , Diabetes, Gestational/physiopathology , Infant, Newborn, Diseases/epidemiology , Pregnancy Complications/epidemiology , Adult , Age of Onset , Female , Follow-Up Studies , Gestational Age , Humans , Incidence , Infant , Infant, Newborn , Infant, Newborn, Diseases/diagnosis , Japan/epidemiology , Pregnancy , Pregnancy Complications/diagnosis , Pregnancy Outcome , Retrospective Studies
7.
J Am Heart Assoc ; 8(15): e012093, 2019 08 06.
Article in English | MEDLINE | ID: mdl-31345083

ABSTRACT

Background Amlodipine is used for the treatment of hypertension, but reports on its use in early pregnancy are limited. Methods and Results In the present study, we recruited 231 women with chronic hypertension, including those who received amlodipine or other antihypertensives during early pregnancy, and investigated frequencies of morphologic abnormalities in their 231 offspring. Specifically, we evaluated 48 neonates exposed to amlodipine in the first trimester (amlodipine group, Group A), 54 neonates exposed to antihypertensives other than amlodipine (other antihypertensive group, Group O), and 129 neonates not exposed to antihypertensives (no-antihypertensive group, Group N). The number of morphologic abnormalities of offspring in each group were 2 in Group A (4.2%; 95% CI, 0.51-14.25); 3 in Group O (5.6%; 95% CI, 1.16-15.39) and 6 in Group N (4.7%; 95% CI, 1.73-9.85). The odds ratio of the primary outcome comparing Group A and Group O was 0.74 (95% CI: 0.118-4.621) and Group A and Group N was 0.89 (95% CI: 0.174-4.575). Conclusions The odds of birth defects in Group A in the first trimester were not significantly different from those with or without other antihypertensives.


Subject(s)
Abnormalities, Drug-Induced/epidemiology , Amlodipine/adverse effects , Antihypertensive Agents/adverse effects , Hypertension/drug therapy , Pregnancy Complications, Cardiovascular/drug therapy , Abnormalities, Drug-Induced/etiology , Aged , Amlodipine/therapeutic use , Antihypertensive Agents/therapeutic use , Chronic Disease , Female , Follow-Up Studies , Humans , Infant, Newborn , Male , Middle Aged , Pregnancy , Pregnancy Trimester, First , Prospective Studies
8.
Mod Rheumatol ; 28(4): 690-696, 2018 Jul.
Article in English | MEDLINE | ID: mdl-28880700

ABSTRACT

OBJECTIVE: The aims of this study are to determine the incidence of congenital heart block (CHB) in the Japanese population and identify maternal factors predicting fetal CHB in anti-Ro/SSA antibody positive pregnancy. METHODS: A retrospective study was performed using 52,147 clinical records of pregnancies followed in a single center. For 183 anti-Ro/SSA antibody-positive women, anti-Ro52 and Ro60 antibodies were measured, and the odds of CHB in relation to maternal clinical features were calculated by multivariate analysis. The receiver-operating characteristic (ROC) curves for predicting CHB were constructed for the titers of anti-Ro/SSA, anti-Ro52 and anti-Ro60 antibodies. RESULTS: Fetal CHB occurred in two pregnancies among those without known risks such as positive anti-Ro/SSA antibody or previous CHB-affected pregnancy, suggesting an incidence similar to that in Caucasian populations. As for the anti-Ro/SSA antibody positive pregnancies, the titers of anti-Ro/SSA, anti-Ro52 and anti-Ro60 antibodies were independent risk factors for fetal CHB and the use of corticosteroids before 18 gestational weeks was an independent protective factor. The area under the ROC was 0.84, 0.73 and 0.74 for anti-Ro52, anti-Ro60 and anti-Ro/SSA antibodies, respectively. CONCLUSION: CHB occurred in two among approximately 50,000 pregnancies without known risks such as positive anti-Ro/SSA antibody or previous delivery of CHB-affected babies. Measurement of anti-Ro52 antibody levels may be helpful in extracting a risk group of delivering CHB infants in the anti-Ro/SSA antibody positive pregnancy.


Subject(s)
Antibodies, Antinuclear/blood , Fetal Diseases/blood , Heart Block/congenital , Adult , Biomarkers/blood , Female , Fetal Diseases/epidemiology , Heart Block/blood , Heart Block/epidemiology , Humans , Incidence , Male , Pregnancy , Retrospective Studies , Risk Factors
10.
Mod Rheumatol ; 26(4): 569-75, 2016 Jul.
Article in English | MEDLINE | ID: mdl-26457409

ABSTRACT

OBJECTIVE: To determine the maternal predictive factors for fetal congenital heart block (CHB) in pregnancy in mothers positive for anti-SS-A antibodies. METHODS: The Research Team for Surveillance of Autoantibody-Exposed Fetuses and Treatment of Neonatal Lupus Erythematosus, the Research Program of the Japan Ministry of Health, Labor and Welfare, performed a national survey on pregnancy of mothers positive for anti-SS-A antibodies. We analyzed 635 pregnant mothers who tested positive for anti-SS-A antibodies before conception but had no previous history of fetal CHB. We performed univariate and multivariate analysis (models 1, 2, and 3 using different set of independent variables) investigated the relation between risk of fetal CHB and maternal clinical features. RESULTS: Of the 635 pregnant mothers, fetal CHB was detected in 16. Univariate analysis showed that fetal CHB associated with use of corticosteroids before conception (OR 3.72, p = 0.04), and negatively with use of corticosteroids (equivalent doses of prednisolone (PSL), at ≥10 mg/day) after conception before 16-week gestation (OR 0.17, p = 0.03). In multivariate analysis, model 1 identified the use of corticosteroids before conception (OR 4.28, p = 0.04) and high titer of anti-SS-A antibodies (OR 3.58, p = 0.02) as independent and significant risk factors, and model 3 identified use of corticosteroids (equivalent doses of PSL, at ≥10 mg/day) after conception before 16-week gestation as independent protective factor against the development of fetal CHB (OR 0.16, p = 0.03). Other maternal clinical features did not influence the development of fetal CHB. CONCLUSION: The results identified high titers of anti-SS-A antibodies and use of corticosteroids before conception as independent risk factors, and use of corticosteroids (equivalent doses of PSL, at ≥10 mg/day) after conception before 16-week gestation as an independent protective factor for fetal CHB.


Subject(s)
Antibodies, Antinuclear/blood , Glucocorticoids , Heart Block/congenital , Lupus Erythematosus, Systemic/congenital , Adult , Autoantibodies/blood , Dose-Response Relationship, Drug , Female , Glucocorticoids/administration & dosage , Glucocorticoids/adverse effects , Health Surveys , Heart Block/diagnosis , Heart Block/etiology , Humans , Infant, Newborn , Japan , Lupus Erythematosus, Systemic/blood , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/diagnosis , Lupus Erythematosus, Systemic/drug therapy , Pregnancy , Pregnancy Complications/blood , Pregnancy Complications/diagnosis , Pregnancy Complications/drug therapy , Protective Factors , Risk Factors , Statistics as Topic
11.
Hypertens Pregnancy ; 34(2): 209-20, 2015 May.
Article in English | MEDLINE | ID: mdl-25774557

ABSTRACT

OBJECTIVE: To assess the present status of clinical care for postpartum patients with hypertensive disorders of pregnancy (HDP) in Japan. METHODS: We conducted a nationwide questionnaire survey of obstetricians, internists and hypertension specialists and analyzed 686 valid responses. RESULTS: Though HDP is widely known as a risk factor for subsequent hypertension and cardiovascular disease, over one-third of obstetricians terminated their postpartum follow-up of HDP patients without referring them to other departments. CONCLUSION: It is important to establish an effective referral system, whereby patients with HDP can be smoothly transferred to primary care or a specialist physician after childbirth for long-term monitoring and management of blood pressure.


Subject(s)
Antihypertensive Agents/therapeutic use , Cardiovascular Diseases/prevention & control , Hypertension, Pregnancy-Induced/drug therapy , Hypertension, Pregnancy-Induced/epidemiology , Postnatal Care/statistics & numerical data , Referral and Consultation , Adult , Female , Humans , Japan/epidemiology , Postpartum Period , Pregnancy , Risk Factors , Surveys and Questionnaires
12.
Rinsho Byori ; 62(4): 324-31, 2014 Apr.
Article in Japanese | MEDLINE | ID: mdl-25022061

ABSTRACT

Neonatal lupus erythematosus (NLE) is a rare syndrome caused by the transplacental passage of maternal autoantibodies. Anti SS-A antibodies of a mother with Sjögren syndrome are associated with congenital heart block (CHB) in the newborns with NLE. The purpose of this study was to investigate the utility of maternal antibody titers for SS-A, Ro52 and Ro60 in mothers of newborns with CHB. The study involved a total of 304 cases, 25 from mothers of newborns with CHB, 104 from mothers of newborns without and 175 from mothers suspected to have connective tissue diseases. All sera were tested with the EliA SS-A, EliA Ro52, EliA Ro60, MESACUP Ro52 and MESACUP Ro60. The concordance rate of Ro52 assays was 93.4%, whereas Ro60 assays showed a lower concordance rate (74.7%). The areas under the curve (AUC) of the EliA assays were higher than those of the MESACUP assays. The optimal cut-off values for EliA SS-A/Ro and EliA Ro60 as derived from the ROC analysis were 2027 U/mL and 2446 U/mL, respectively. The sensitivity and specificity for EliA SS-A using optimal cut-off values were 96.0% and 92.3%, respectively. A titer of 90% positive predictive value for EliA SS-A was reached at a cut-off of 9897.1 U/mL, corresponding to sensitivity and specificity values of 36.0% and 100%, respectively. In conclusion, the optimal cut-off value for EliA SS-A is likely to be useful for application in clinical practice for the EliA SS-A measurements in mothers to evaluate the risk of NLE for their newborns.


Subject(s)
Antibodies, Antinuclear/immunology , Autoantibodies/immunology , Heart Block/congenital , Lupus Erythematosus, Systemic/congenital , Sjogren's Syndrome/immunology , Antibody Specificity , Female , Heart Block/immunology , Humans , Lupus Erythematosus, Systemic/immunology
13.
Endocr J ; 61(8): 759-64, 2014.
Article in English | MEDLINE | ID: mdl-24838051

ABSTRACT

The present study was performed to evaluate pregnancy outcomes in women with type 1 and type 2 diabetes mellitus (DM) in Japan. This multi-institutional retrospective study was conducted in 40 general hospitals in Japan during 2003-2009. We evaluated 369 and 579 pregnant women with type 1 and type 2 DM, respectively, and compared pregnancy outcomes between the two groups. Glycosylated hemoglobin levels in the first trimester did not differ significantly between the studied groups. Gestational weight gain was lower in type 2 DM than in type 1 DM. Although there were no significant differences in perinatal outcomes between the groups, the primary cesarean section rate was higher in type 2 DM than in type 1 DM. Multiple logistic regression analysis revealed that primigravida status, pre-gestational body mass index (BMI), gestational weight gain, chronic hypertension, and microvascular disease including diabetic retinopathy or nephropathy were associated with onset of pregnancy-induced hypertension. Further, pre-gestational BMI was associated with the need for primary cesarean section. This study demonstrated that no differences were observed in the rates of perinatal mortality and congenital malformation between pregnant women with type 1 DM and type 2 DM; however, women with type 2 DM displayed a higher risk of primary cesarean section.


Subject(s)
Diabetes Mellitus, Type 1/epidemiology , Diabetes Mellitus, Type 2/epidemiology , Pregnancy Outcome/epidemiology , Pregnancy in Diabetics/epidemiology , Adult , Body Mass Index , Cesarean Section/statistics & numerical data , Female , Humans , Hypertension, Pregnancy-Induced/epidemiology , Japan/epidemiology , Pregnancy , Pregnancy in Diabetics/diagnosis , Retrospective Studies , Weight Gain , Young Adult
14.
Endocr J ; 61(4): 373-80, 2014.
Article in English | MEDLINE | ID: mdl-24476982

ABSTRACT

The aim of this study was to determine the effects of pre-gestational body mass index on pregnancy outcomes of women with gestational diabetes in Japan. A multi-institutional retrospective study was performed. We examined pregnant women who met the former criteria for gestational diabetes in Japan, receiving dietary intervention with self-monitoring of blood glucose with or without insulin therapy. Women with gestational diabetes were divided into three groups according to pre-gestational body mass index: body mass index <25 (control group), 25 ≤ body mass index <30 (overweight group), body mass index ≥30 (obese group). Data from a total of 1,758 eligible women were collected from 40 institutions. Participants included 960 controls, 426 overweight women, and 372 obese women with gestational diabetes. Gestational weight gain was highest in the control and lowest in the obese group. The prevalences of chronic hypertension and pregnancy induced hypertension were higher in the overweight and obese groups than in the control group. Multiple logistic regression analysis revealed pre-gestational body mass index, gestational weight gain, chronic hypertension, and nulliparity to be associated with the onset of pregnancy induced hypertension, while the 75-g OGTT results were unrelated to pregnancy induced hypertension. The prevalence of large-for-gestational age was lower in infants born to obese women than in those born to overweight or control women. The present results suggest that medical interventions for obese women with gestational diabetes may contribute to reducing the prevalence of large-for-gestational age but would not achieve marked reductions in maternal complications.


Subject(s)
Diabetes, Gestational/therapy , Diet, Diabetic , Hypertension, Pregnancy-Induced/prevention & control , Hypoglycemic Agents/therapeutic use , Insulin/therapeutic use , Obesity/physiopathology , Overweight/physiopathology , Birth Weight , Blood Glucose Self-Monitoring , Body Mass Index , Combined Modality Therapy , Diabetes, Gestational/blood , Diabetes, Gestational/epidemiology , Diabetes, Gestational/etiology , Female , Humans , Hypertension, Pregnancy-Induced/epidemiology , Hypertension, Pregnancy-Induced/etiology , Japan/epidemiology , Obesity/complications , Overweight/complications , Pregnancy , Pregnancy Outcome , Prevalence , Retrospective Studies , Risk Factors , Weight Gain
15.
Mod Rheumatol ; 23(4): 653-8, 2013 Jul.
Article in English | MEDLINE | ID: mdl-22760476

ABSTRACT

OBJECTIVE: Fetal congenital complete heart block (CHB) is irreversible and is associated with significant mortality and morbidity. Anti-SS-A antibodies in the maternal sera are involved in its pathogenesis; however, the predictive value of the antibody titer and its role in prediction of this complication are controversial. The aim of this study was to determine the predictive value of maternal anti-SS-A antibodies on the development of fetal CHB. METHODS: A retrospective chart review was performed for 189 cases of positive anti-SS-A antibodies determined by the double immunodiffusion (DID) method, and included 17 patients that developed fetal CHB. The relationship between the appearance of CHB and the anti-SS-A antibodies titer was examined. RESULTS: An anti-SS-A antibodies titer of 1:32 or higher was identified by analyzing the receiver-operating characteristics (area under curve 0.72) curve. An anti-SS-A antibodies titer of 32 or more times greater than the upper limit by DID was a risk factor for fetal CHB (odds ratio 27.77, 95% confidence interval (CI) 1.91-21.02, P < 0.05) in the multivariate analysis. Among 107 cases of anti-SS-A antibodies titers of 1:32 or higher, 65 patients (60.7%) were treated with oral steroids. Of these, four patients had CHB (6.2%). This rate of CHB was significantly lower (P < 0.01) than the rate in patients not treated with steroids. CONCLUSION: An anti-SS-A antibodies titer of 1:32 or higher in the maternal sera by DID was an independent risk factor for fetal CHB. In these patients, either antenatally administered prednisolone or betamethasone, was associated with a lower risk of fetal CHB.


Subject(s)
Antibodies, Anti-Idiotypic/analysis , Antibodies, Antinuclear/immunology , Heart Block/congenital , Pregnancy Complications/immunology , Adult , Female , Heart Block/immunology , Humans , Predictive Value of Tests , Pregnancy , Retrospective Studies
16.
17.
Int J Hematol ; 94(2): 150-155, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21811774

ABSTRACT

Deep vein thrombosis (DVT) is a serious pregnancy-related complication. Recent studies indicate that the genetic background for DVT differs with ethnicity. In our study, we enrolled 18 consecutive Japanese patients who had developed DVT during pregnancy and postpartum. We performed a genetic analysis of three candidate genes for DVT, protein S, protein C and antithrombin, in these patients. We found that four patients had missense mutations in the protein S gene, including the K196E mutation in two patients, the L446P mutation in one patient, and the D79Y and T630I mutations in one patient, as well as one patient with the C147Y mutation in the protein C gene. All five patients with genetic mutations had DVT in their first two trimesters. Nine of the patients without genetic mutations developed DVT in the first two trimesters, and four in the postpartum period. Thus, genetic mutations in the protein S gene were predominant in pregnant Japanese DVT women, and DVT in pregnant women with genetic mutations occurred more frequently at the early stage of pregnancy than postpartum. Considering the rapid decrease in protein S activity during pregnancy, we may need to assess thrombophilia in women before pregnancy.


Subject(s)
Mutant Proteins/analysis , Pregnancy Complications, Cardiovascular/genetics , Protein S/genetics , Venous Thrombosis/genetics , Asian People/genetics , Biomarkers , Female , Genetic Testing , Humans , Postpartum Period/blood , Postpartum Period/genetics , Pregnancy , Pregnancy Complications, Cardiovascular/blood , Pregnancy Complications, Cardiovascular/ethnology , Thrombophilia/diagnosis , Thrombophilia/genetics , Venous Thrombosis/blood , Venous Thrombosis/ethnology
18.
Hum Reprod ; 26(2): 466-72, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21156724

ABSTRACT

BACKGROUND: No epidemiological studies have examined risk factors for early spontaneous abortions among Japanese women. In this matched case-control study, we investigated the associations of reproductive, physical, and lifestyle characteristics of women and their husbands with early spontaneous abortion <12 weeks of gestation. METHODS: Information was collected through medical records for 430 cases of early spontaneous abortion and 860 controls of term delivery. Two controls were individual-matched to one case according to maternal age (± 3 years) and calendar year of events (either early spontaneous abortion or delivery). Multivariable conditional odds ratios (ORs) and 95% confidence interval (CI) were calculated with conditional logistic-regression. RESULTS: The risk of early spontaneous abortions was higher for women with a past history of early spontaneous abortions; OR was 1.98 (95% CI: 1.35, 2.89) for one previous spontaneous abortion, 2.36 (95% CI: 1.47, 3.79) for two, and 8.73 (95% CI: 5.22, 14.62) for three or more. Other factors also influence risk; an OR of 2.39 (95% CI: 1.26, 4.25) was found for women who smoked, and 1.65 (95%CI: 1.17, 2.35) for women working outside the home. CONCLUSIONS: Our finding suggests that for Japanese women, smoking and working may be important public health issue targets for the prevention of early spontaneous abortions.


Subject(s)
Abortion, Spontaneous/etiology , Abortion, Induced/adverse effects , Adolescent , Adult , Case-Control Studies , Female , Humans , Japan/epidemiology , Maternal Age , Middle Aged , Pregnancy , Pregnancy Trimester, First , Risk Factors , Smoking/adverse effects , Women, Working/statistics & numerical data
19.
J Pediatr Endocrinol Metab ; 23(9): 913-20, 2010 Sep.
Article in English | MEDLINE | ID: mdl-21175090

ABSTRACT

BACKGROUND: Adiponectin has been shown to be inversely related to birth weight in schoolchildren and adolescents. However, the available information regarding a relation between birth size and adiponectin in infants and preschoolers is limited. METHODS: A longitudinal study was conducted among healthy Japanese children, and serum adiponectin levels were measured at consecutive visits. The effect of sex, gestational age, birth length, birth weight, or placental weight on adiponectin was analyzed by using a linear mixed model for repeated measures. RESULTS: Eighty-three children were evaluated. The age range at the first visit was 0.07-5.3 years. A total number of 227 measurements were made, 1-12 per subject (median, 3) and the duration of follow-up ranged from 1 day to 2.3 years (median, 1.0 years). The subjects were divided into four groups according to the age at the first visit: (1) 0-2 months (n = 29), (2) 3 months to 1 year (n = 17), (3) 2-3 years (n = 19) and (4) 4-5 years (n = 18). In the multivariate model, birth length (coefficient = 3.94, 95% CI, 0.23-7.65) was an independent predictor of serum adiponectin levels in subjects aged 0-2 months. Gestational age (3.53, 1.14-5.92), birth length (-2.71, -4.90 to -0.53) and placental weight (2.58, 0.86-4.29) were independent predictors of serum adiponectin levels in subjects aged 4-5 years. CONCLUSION: Birth length, not birth weight, is an independent predictor of serum adiponectin levels in Japanese young children.


Subject(s)
Adiponectin/blood , Body Height , Asian People , Birth Weight , Child, Preschool , Female , Gestational Age , Humans , Infant , Infant, Newborn , Male , Sex Characteristics
20.
Diabetes Care ; 33(3): 509-11, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20032277

ABSTRACT

OBJECTIVE We have already reported that A1C is elevated because of iron deficiency in late pregnancy among nondiabetic pregnant women. This report examined whether the same phenomenon is observed in pregnant women with diabetes. RESEARCH DESIGN AND METHODS This longitudinal study was conducted in 17 pregnant women with diabetes (20-35 weeks of pregnancy). A1C, serum glycated albumin, erythrocyte indexes, and iron metabolism indexes were measured. RESULTS A1C levels were significantly increased in late pregnancy, whereas serum glycated albumin showed no significant changes. Glycated albumin/A1C ratio, mean corpuscular hemoglobin, serum transferrin saturation, and serum ferritin were significantly decreased in late pregnancy. Serum transferrin saturation showed a significant positive correlation with glycated albumin/A1C ratio. CONCLUSIONS A1C levels, but not serum glycated albumin levels, are elevated in late pregnancy because of iron deficiency in diabetic women. Serum glycated albumin may offer an adequate marker for glycemic control during pregnancy.


Subject(s)
Anemia, Iron-Deficiency/blood , Diabetes, Gestational/blood , Glycated Hemoglobin/metabolism , Pregnancy Complications, Hematologic/blood , Pregnancy in Diabetics/blood , Serum Albumin/metabolism , Adult , Anemia, Iron-Deficiency/metabolism , Diabetes Complications/blood , Diabetes Complications/metabolism , Diabetes, Gestational/metabolism , Erythrocyte Count , Female , Glycation End Products, Advanced , Humans , Iron/blood , Iron/metabolism , Longitudinal Studies , Pregnancy , Pregnancy Complications, Hematologic/metabolism , Pregnancy Trimester, Second/blood , Pregnancy Trimester, Second/metabolism , Pregnancy Trimester, Third/blood , Pregnancy Trimester, Third/metabolism , Pregnancy in Diabetics/metabolism , Up-Regulation , Glycated Serum Albumin
SELECTION OF CITATIONS
SEARCH DETAIL
...